Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 13/20 | 0.46 |
| ▸ | LONP1 | P36776 | 7/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 4/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 4/20 | 0.46 |
| ▸ | PSMB9 | P28065 | 4/20 | 0.46 |
| ▸ | PSMB10 | P40306 | 4/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | CTSG | P08311 | 2/20 | 0.46 |
| ▸ | CMA1 | P23946 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PSMB11 | A5LHX3 | 3/20 | 0.41 |
| ▸ | PSMA7 | O14818 | 3/20 | 0.41 |
| ▸ | PSMA1 | P25786 | 3/20 | 0.41 |
| ▸ | PSMA2 | P25787 | 3/20 | 0.41 |
| ▸ | PSMA3 | P25788 | 3/20 | 0.41 |
| ▸ | PSMA4 | P25789 | 3/20 | 0.41 |
| ▸ | PSMA5 | P28066 | 3/20 | 0.41 |
| ▸ | PSMB4 | P28070 | 3/20 | 0.41 |
| ▸ | PSMB6 | P28072 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930110 | 0.84 | NPC1 (0.40) | — | |
| SCHEMBL10246136 | 0.84 | PSMB5 (0.53) | PSMB5LONP1PSMB1PSMB2CLPP | |
| SCHEMBL10243566 | 0.84 | PSMB5 (0.53) | PSMB5LONP1PSMB1PSMB2CLPP | |
| SCHEMBL2935449 | 0.84 | PSMB5 (0.67) | PSMB5LONP1PSMB1PSMB8PSMB9 | |
| SCHEMBL2932843 | 0.83 | LONP1 (0.50) | PSMB5LONP1PSMB1PSMB8PSMB9 | |
| SCHEMBL2930109 | 0.83 | L3MBTL1 (0.36) | — | |
| SCHEMBL8257202 | 0.82 | PSMB5 (0.67) | PSMB5LONP1PSMB1PSMB8PSMB9 | |
| SCHEMBL2926138 | 0.82 | PSMB5 (0.67) | PSMB5LONP1PSMB1PSMB8PSMB9 | |
| SCHEMBL2931869 | 0.81 | PSMB5 (0.53) | PSMB5LONP1PSMB1PSMB8PSMB9 | |
| SCHEMBL2934069 | 0.81 | PSMB5 (0.51) | PSMB5LONP1PSMB1PSMB8PSMB9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846424-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-01-27 | — | — | EP | claimed |
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| WO-2006086600-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885LONP1 277/4885PSMB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.